Pirini Francesca, Cortesi Michela, Tumedei Maria Maddalena, Zanoni Michele, Ravaioli Sara, Bravaccini Sara
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Front Cell Dev Biol. 2023 Jan 4;10:1048360. doi: 10.3389/fcell.2022.1048360. eCollection 2022.
The role of the intestinal microbiota in the promotion, progression, and response to therapies is gaining importance, but recent studies confirm the presence of microbiota also in the tumor, thus becoming a component of the tumor microenvironment. There is not much knowledge on the characteristics and mechanisms of action of the tumor resident microbiota, but there are already indications of its involvement in conditioning the response to therapies. In this review, we discuss recent publications on the interaction between microbiota and anticancer treatments, mechanisms of resistance and possible strategies for manipulating the microbiota that could improve treatments in a personalized medicine perspective.
肠道微生物群在肿瘤的发生发展及对治疗的反应中所起的作用日益重要,而最近的研究证实肿瘤中也存在微生物群,因此它成为肿瘤微环境的一个组成部分。目前对于肿瘤内常驻微生物群的特征和作用机制了解不多,但已有迹象表明其参与了对治疗反应的调节。在本综述中,我们讨论了关于微生物群与抗癌治疗之间相互作用、耐药机制以及从个性化医疗角度操纵微生物群以改善治疗效果的可能策略的最新出版物。